Ask a room of executives why market entries fail and you will hear about tariffs, regulations and exchange rates. Those matter. But after three decades of advising companies moving in both directions across the Pacific, I can tell you the more common causes are quieter: the wrong local partner, a misread regulatory signal, a pricing model imported unchanged from home, and a headquarters that loses patience eighteen months before the market turns.

Translation is the real work

Cross-border expansion fails most often not on numbers but on translation — of law, of custom, of expectation. A contract that is airtight in Delaware may be a conversation starter elsewhere. A distribution partner’s enthusiasm may be genuine and still mean something different than you think it means. The work of market entry advisory is largely the work of translating between systems that use similar words for dissimilar things.

This is why the first question I ask any company considering a new market is not “what is your product?” but “who is your translator?” Not of language — of systems. Someone on your side of the table must have operated inside both environments long enough to know which assurances are binding, which approvals actually gate the deal, and which signals matter versus which merely make headlines.

Partner selection: the five-year test

Most joint ventures and distribution partnerships are chosen on the strength of a first impression and a revenue projection. A better filter is what I call the five-year test: will this partner still be there, still solvent, still aligned with you, in year five? That question forces diligence on the things that predict endurance — the partner’s other commitments, their standing with local authorities, their succession picture, and whether your success helps or threatens their core business.

A partner whose interests merely overlap with yours today will drift. A partner whose interests are structurally tied to your growth will stay. Structure beats sentiment, every time.

Regulatory reality versus regulatory theater

Every market has two regulatory systems: the one written down and the one that actually operates. Neither is optional, but they are not the same thing, and companies that study only the written version routinely stall. The practical questions are always: which approvals are truly gating, who grants them, what is the realistic timeline, and what do the last ten companies that tried this actually experience?

Good advisors answer those questions with cases, not theory. If your advisor cannot name the last three companies that made this exact journey and tell you what surprised them, you have hired a researcher, not a guide.

Price for the market you are entering

The most common self-inflicted wound is imported pricing. Companies calculate what they need to earn based on home-market costs and habits, then discover the local competitive set operates on entirely different economics. Enter with the cost structure the market requires, or do not enter. A market will teach you its economics either way; tuition is cheaper when paid up front.

Patience is a budget line

Finally, the quiet killer: time. Most successful market entries look unremarkable for two to three years while distribution, trust and word-of-mouth compound. Boards that budget for twelve quarters of investment get results. Boards that revisit the decision every two quarters get neither results nor a clean exit. If the commitment horizon is shorter than the market’s trust horizon, save the money.

None of this is glamorous. That is rather the point. Market entry done right is a discipline of details — and the details are learnable, from people who have carried them across the bridge before.

Benjamin Wey
Benjamin Wey

American financier and CEO of New York Global Group, bridging U.S. and Chinese capital markets for more than three decades. Full bio